Opinion of the Transparency Council –
At its meeting on 31 March 2025, the Transparency Council adopted opinion No. 54/2025 on the reimbursement of drugs containing the active substance peginterferon alfa-2a for indications, dosages or administration methods other than those specified in the Summary of Product Characteristics, i.e. mycosis fungoides; Sezary’s disease; polycythemia vera; chronic myelogenous leukemia; essential thrombocythemia